Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead Sciences

Showing 15 posts of 23 posts found.

drug-trials

Gilead Foundation awards $6.5m in grants to support STEM education

September 26, 2025
Research and Development Funding and Investment, Gilead Sciences, stem

Gilead Sciences has committed over $6.5m in grant funding towards improving science, technology, engineering and maths (STEM) education, the company …

News

Gilead’s Veklury recommended by NICE for COVID-19 treatment

April 9, 2024
Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …

News

Gilead and Merck share data from phase 2 trial of HIV treatment

March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

News

Gilead and Compugen enter exclusive license agreement for immunotherapy programme

December 20, 2023
Research and Development Gilead Sciences, Immunology, License Agreement, compugen, immunology

Gilead Sciences and Compugen have announced that they have entered an exclusive license agreement for Compugen’s potential first in class, …

News
gilead-sciences

Nimbus Therapeutics receives $200 million payment from Gilead

November 2, 2016
Research and Development Gilead Sciences, Nimbus Therapeutics, nash

Nimbus Therapeutics only signed a deal with Gilead Sciences back in April of this year and yet have already received …

News
gilead-sciences

Gilead’s drug boosted by positive Phase II trials and aims to move forward

October 21, 2016
Medical Communications Gilead, Gilead Sciences, clinical trials, fatty liver disease

Gilead Sciences has announced positive results from three Phase II studies upon their drug GS-4997, otherwise known as selonsertib. The …

News
gilead-sciences

Gilead Sciences says Phase III trials for chronic HBV drug meet primary endpoints

April 15, 2016
Gilead Sciences, US FDA, chronic hepatitis B, drug trial

Biotech firm Gilead Sciences (NYSE: GILD) on Friday announced positive results from late-stage trials for its drug to treat chronic …

News
gilead-sciences

Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion

April 5, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions

Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …

News
msd

Gilead must pay MSD $200m in hep C drug patent case

March 29, 2016
Manufacturing and Production, Sales and Marketing Gilead Sciences, MSD, Solvadi, harvoni

A Californian federal jury has ordered Gilead Sciences to pay MSD and Ionis $200 million for infringing on patents relating …

News
zydelig_gilead

Gilead cancer boss departs after safety concerns halt Zydelig trials

March 18, 2016
Medical Communications, Research and Development Gilead Sciences, zydelig

In the wake of the halting of six clinical trials of its blood cancer drug Zydelig due to safety concerns, …

News
gilead-sciences

EMA starts review of Gilead Sciences’ Zydelig following safety concerns

March 14, 2016
Research and Development, Sales and Marketing EMA, Gilead Sciences, blood cancer, clinical trials, zydelig

Regulators in Europe have initiated a safety review of Gilead Sciences’ (Nasdaq: GILD) blood cancer drug Zydelig (idelalisib) following reports …

News
gilead-sciences

FDA approves Gilead’s Odefsey for treatment of HIV-1 infection

March 2, 2016
Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …

News
gilead-sciences

Positive CHMP opinion for Gilead’s Descovy

February 26, 2016
Research and Development Gilead Sciences

The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has adopted a positive opinion …

News
gilead-sciences

Gilead announces HIV regimen trial results

February 25, 2016
Medical Communications, Research and Development, Sales and Marketing Gilead Sciences

Gilead Sciences has reported 48-week Phase III trial results suggesting fixed-dose Emtriva and tenofovir alafenamide (F/TAF) combinations matched its Truvada …

News
gilead-sciences

FDA approves Gilead’s Harvoni in two new indications

February 18, 2016
Research and Development Gilead Sciences, MSD, harvoni, hepatitis C

The hepatitis C treatment battle had its latest development yesterday, with the FDA awarding Gilead Science’s market-leading drug Harvoni (ledipasvir/sofosbuvir) …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026